FOSUN PHARMA's Application for Traditional Chinese Medicine New Drug Accepted for Review

Stock News05-13

FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products Administration. The application was submitted by the company's controlled subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd. This drug is indicated for nourishing blood, activating blood circulation, and dispelling blood stasis, intended for the treatment of blood deficiency and blood stasis syndrome, with symptoms such as irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual quality, abdominal pain, and bloating. The prescription originates from the Taohong Siwu Tang formula recorded in the Qing Dynasty medical text "Fuke Bingjian" and is included in the National Administration of Traditional Chinese Medicine's "Catalogue of Ancient Classical Famous Formulas (First Batch)". As of April 2026, the cumulative R&D investment by the Group for this drug amounts to approximately RMB 6.96 million (unaudited). As of the date of this announcement, only two Taohong Siwu Tang Granules products have been approved for marketing in mainland China, with approval dates in April 2025 and April 2026, respectively. Currently, sales data for these products in mainland China for the year 2025 is not yet available in the IQVIA CHPA database.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147733241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147733241","market":"fut","top_or_hot":-1,"title":"FOSUN PHARMA's Application for Traditional Chinese Medicine New Drug Accepted for Review","media":"Stock News","content":"<p>FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products Administration. The application was submitted by the company's controlled subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd. This drug is indicated for nourishing blood, activating blood circulation, and dispelling blood stasis, intended for the treatment of blood deficiency and blood stasis syndrome, with symptoms such as irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual quality, abdominal pain, and bloating. The prescription originates from the Taohong Siwu Tang formula recorded in the Qing Dynasty medical text \"Fuke Bingjian\" and is included in the National Administration of Traditional Chinese Medicine's \"Catalogue of Ancient Classical Famous Formulas (First Batch)\". As of April 2026, the cumulative R&D investment by the Group for this drug amounts to approximately RMB 6.96 million (unaudited). As of the date of this announcement, only two Taohong Siwu Tang Granules products have been approved for marketing in mainland China, with approval dates in April 2025 and April 2026, respectively. Currently, sales data for these products in mainland China for the year 2025 is not yet available in the IQVIA CHPA database.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Application for Traditional Chinese Medicine New Drug Accepted for Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Application for Traditional Chinese Medicine New Drug Accepted for Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-13 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products Administration. The application was submitted by the company's controlled subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd. This drug is indicated for nourishing blood, activating blood circulation, and dispelling blood stasis, intended for the treatment of blood deficiency and blood stasis syndrome, with symptoms such as irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual quality, abdominal pain, and bloating. The prescription originates from the Taohong Siwu Tang formula recorded in the Qing Dynasty medical text \"Fuke Bingjian\" and is included in the National Administration of Traditional Chinese Medicine's \"Catalogue of Ancient Classical Famous Formulas (First Batch)\". As of April 2026, the cumulative R&D investment by the Group for this drug amounts to approximately RMB 6.96 million (unaudited). As of the date of this announcement, only two Taohong Siwu Tang Granules products have been approved for marketing in mainland China, with approval dates in April 2025 and April 2026, respectively. Currently, sales data for these products in mainland China for the year 2025 is not yet available in the IQVIA CHPA database.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"","article_id":"1147733241","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147733241","pubTimestamp":1778672105,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","BK0096":"民营医院","BK1515":"抗疫概念","BK0188":"融资融券","BK0239":"医药制造","BK0012":"证金概念","BK1593":"医美概念股","BK1191":"制药","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","02196":"复星医药","BK0028":"国家队"},"translate_title":"复星医药中药新药申请获审评受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products Administration. The application was submitted by the company's controlled subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd. This drug is indicated for nourishing blood, activating blood circulation, and dispelling blood stasis, intended for the treatment of blood deficiency and blood stasis syndrome, with symptoms such as irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual quality, abdominal pain, and bloating. The prescription originates from the Taohong Siwu Tang formula recorded in the Qing Dynasty medical text \"Fuke Bingjian\" and is included in the National Administration of Traditional Chinese Medicine's \"Catalogue of Ancient Classical Famous Formulas (First Batch)\". As of April 2026, the cumulative R&D investment by the Group for this drug amounts to approximately RMB 6.96 million (unaudited). As of the date of this announcement, only two Taohong Siwu Tang Granules products have been approved for marketing in mainland China, with approval dates in April 2025 and April 2026, respectively. Currently, sales data for these products in mainland China for the year 2025 is not yet available in the IQVIA CHPA database.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147733241","isCrawlerRequest":true}